供卵周期中的临床结局:GnRH拮抗剂与微粒化黄体酮行卵巢刺激比较
该回顾性分析纳入2018年1月至2022年12月的1368个供卵周期,比较口服天然微粒化黄体酮与GnRH拮抗剂预防早发LH峰的供卵者实验室结局及匹配受者的临床结局。两组的活产率相近(拮抗剂组47.2% vs 微粒化黄体酮组44.6%),微粒化黄体酮组的获卵数和成熟卵数更高,但卵母细胞成熟率更低,受精率和可用胚胎数更高。
要点
- 供卵者口服微粒化黄体酮与GnRH拮抗剂的刺激时长和促性腺激素总量相近。
- 微粒化黄体酮组的获卵数、成熟卵数、受精率和可用胚胎数均高于拮抗剂组,卵母细胞成熟率则低于拮抗剂组。
- 匹配受者行新鲜胚胎移植后,两组的活产率相近(47.2% vs 44.6%)。
核心结论
- 两组受者行新鲜胚胎移植后的活产率相近。
- 微粒化黄体酮方案与更高的成熟卵数、更低的卵母细胞成熟率、更高的受精率和可用囊胚数相关。
- 黄体酮预处理可能对供卵周期产生积极影响。
研究设计与样本
- 回顾性分析纳入2018年1月至2022年12月的1368个供卵周期,其中实验室结局793个、匹配受者的临床结局645个。
- 供卵者在早卵泡期开始卵巢刺激,研究组口服天然微粒化黄体酮联合FSH,对照组采用灵活方案的GnRH拮抗剂。
- 主要结局为活产率。
主要发现
- 两组的刺激时长和促性腺激素总量相近。
- 微粒化黄体酮组获卵数15.9 ± 8.5 vs 拮抗剂组13.1 ± 7.9(P < 0.001),成熟卵数12.8 ± 7.3 vs 11.7 ± 7.3(P = 0.003)。
- 微粒化黄体酮组卵母细胞成熟率80.89 ± 16.78% vs 拮抗剂组89.49 ± 14.48%(P < 0.001)。
- 微粒化黄体酮组受精率81.3% vs 拮抗剂组74.3%(P < 0.001),可用胚胎数4.6 ± 2.0 vs 4.1 ± 2.0(P < 0.001)。
- 匹配受者新鲜胚胎移植后的活产率:GnRH拮抗剂组47.2% vs 微粒化黄体酮组44.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: In oocyte donation cycles, does the use of oral natural micronized progesterone (NMP) result in comparable clinical outcomes, compared with gonadotrophin releasing hormone (GnRH) antagonist treatment? DESIGN: Retrospective analysis of 1368 oocyte donation cycles (January 2018 to December 2022), and laboratory (n = 793) and clinical outcomes (n = 645) in matched recipients. Donors initiated ovarian stimulation in early follicular phase. To prevent a premature LH peak, the study group received natural micronized progesterone orally concurrently with FSH administration, whereas the control group began GnRH antagonist treatment in a flexible protocol. Live birth rate was the primary outcome. RESULTS: Duration of stimulation and total gonadotrophins dose were comparable between groups. The NMP group yielded significantly higher retrieved oocytes (15.9 ± 8.5 versus 13.1 ± 7.9; P < 0.001) and mature oocytes (12.8 ± 7.3 versus 11.7 ± 7.3; P = 0.003), and a lower maturation rate (80.89 ± 16.78% versus 89.49 ± 14.48%; P < 0.001). These donors had higher fertilization rates (81.3% versus 74.3%; P < 0.001) and number of usable embryos (4.6 ± 2.0 versus 4.1 ± 2.0; P < 0.001) compared with those treated with a GnRH antagonist. In matched recipients undergoing fresh embryo transfer, reproductive outcomes, including live birth rates, were similar in the GnRH antagonist and NMP groups (47.2% and 44.6%). CONCLUSIONS: Comparable live birth rates were found in fresh embryo transfers for recipients across both groups. The NMP protocol was associated with a higher number of mature oocytes but lower oocyte maturation rate, higher fertilization rates and number of usable blastocysts. Progesterone priming may positively influence oocyte donation cycles.
引用
- Martinez-Moya M, Guerrero J, Ortiz JA, et al. Clinical outcomes in oocyte donation cycles: GnRH-antagonists versus progesterone-primed ovarian stimulation with micronized progesterone. Reprod Biomed Online. 2025. PMID: 40412220. doi:10.1016/j.rbmo.2025.104864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。